Pacer Advisors Inc. Sells 148,738 Shares of Avanos Medical, Inc. $AVNS

Pacer Advisors Inc. trimmed its holdings in shares of Avanos Medical, Inc. (NYSE:AVNS) by 31.1% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 328,805 shares of the company’s stock after selling 148,738 shares during the period. Pacer Advisors Inc. owned approximately 0.71% of Avanos Medical worth $3,801,000 as of its most recent filing with the SEC.

Other hedge funds also recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in shares of Avanos Medical by 4.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock valued at $386,000 after acquiring an additional 1,121 shares during the period. State of Alaska Department of Revenue raised its holdings in shares of Avanos Medical by 8.0% during the second quarter. State of Alaska Department of Revenue now owns 27,504 shares of the company’s stock valued at $336,000 after purchasing an additional 2,039 shares during the period. Russell Investments Group Ltd. raised its holdings in shares of Avanos Medical by 969.3% during the second quarter. Russell Investments Group Ltd. now owns 2,545 shares of the company’s stock valued at $31,000 after purchasing an additional 2,307 shares during the period. Sio Capital Management LLC boosted its position in shares of Avanos Medical by 1.0% during the 2nd quarter. Sio Capital Management LLC now owns 288,849 shares of the company’s stock worth $3,536,000 after purchasing an additional 2,860 shares in the last quarter. Finally, Jane Street Group LLC grew its stake in shares of Avanos Medical by 5.8% in the 2nd quarter. Jane Street Group LLC now owns 56,044 shares of the company’s stock valued at $686,000 after buying an additional 3,062 shares during the period. Institutional investors own 95.17% of the company’s stock.

Avanos Medical Stock Performance

Shares of AVNS opened at $11.33 on Tuesday. The firm has a market capitalization of $525.94 million, a P/E ratio of -1.11 and a beta of 1.09. Avanos Medical, Inc. has a 52 week low of $9.30 and a 52 week high of $17.69. The stock has a 50 day moving average price of $11.49 and a two-hundred day moving average price of $11.64. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.36 and a current ratio of 2.38.

Avanos Medical (NYSE:AVNS) last announced its earnings results on Wednesday, November 5th. The company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.10. Avanos Medical had a positive return on equity of 6.21% and a negative net margin of 67.00%.The company had revenue of $177.80 million for the quarter, compared to analysts’ expectations of $164.50 million. During the same quarter in the previous year, the firm earned $0.33 earnings per share. Avanos Medical’s quarterly revenue was up 4.3% on a year-over-year basis. Avanos Medical has set its FY 2025 guidance at 0.850-0.950 EPS. Equities analysts forecast that Avanos Medical, Inc. will post 1.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently weighed in on AVNS. Wall Street Zen raised Avanos Medical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, November 8th. Zacks Research lowered Avanos Medical from a “hold” rating to a “strong sell” rating in a research report on Monday, December 1st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Avanos Medical in a report on Monday, December 22nd. Two equities research analysts have rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Insider Activity

In other news, SVP Kerr Holbrook sold 15,000 shares of the company’s stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $11.00, for a total value of $165,000.00. Following the completion of the sale, the senior vice president owned 83,860 shares in the company, valued at $922,460. This represents a 15.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 2.64% of the stock is currently owned by insiders.

Avanos Medical Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.